The future of biosimilar use and regulation in Latin America / Research / Biosimilars / Home - GaBi Online

The future of biosimilar use and regulation in Latin America

Biosimilars/Research | Posted 29/08/2014 2 Post your comment

There is a growing uptake of biosimilars in Latin America, but this has not been accompanied by an increase in pharmacovigilance, training or regulation. To address this, an expert panel was put together to discuss the issues involved. The panel’s perspectives on the current status led to six major recommendations drawn up to enhance the safe use of biosimilars across the region [1].

The panel met over two days, with discussion moderated by Dr Richard Kahn, former Chief Scientific and Medical Officer of the American Diabetes Association.

Biological production began in Argentina, Cuba and Mexico shortly after biologicals were introduced in the 1980s. Copies of reference drugs were made because there was no patent law in the region at the time. By the time patents began to expire in Europe, Japan, USA, and other countries belonging to the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, there were about 100 copies of reference products already on sale in Latin America. These were registered as ‘generics’.

Around the year 2000, Europe, USA, Japan and others began discussing how to approve ‘follow-on biologics’. The first countries in Latin America to distinguish between generics and 'follow-on biologics' were Brazil and Venezuela; other countries in the region did not make the distinction until 2010. For countries in the region that have regulations for the approval of biosimilars, World Health Organization (WHO) guidelines have been adopted, but there are still countries in the region that do not differentiate between generics and ‘follow-on biologics’.

In Mexico, until recently, the approval of an intended copy of a biological drug followed the same criteria as that for a generic – so preclinical and clinical data were not required. This means that, although more than 100 million doses of copy drugs were sold between 1993 and 2012, it has not been possible to establish the risk of using these inadequately evaluated drugs.

The expert panel, whose discussion on this topic is published in the Generics and Biosimilars Initiative Journal (GaBI Journal), propose six recommendations they say will significantly enhance the safe use of biosimilars across Latin America (summarized below) [1]:

Enhanced training of regulatory authorities on how to evaluate biosimilars.
Establishment of a region-wide working group to share regulatory experience and plans related to biosimilars (through the WHO Regional Office for the Americas – the Pan American Health Organization [PAHO])
Establishment of a separate working group in each country in Latin America.
Setting up of a dedicated portion on the PRAIS website (PAHO’s Regional Platform on Access and Innovation for Health Technologies) to promote discussion on biosimilars.
Improved pharmacovigilance and training of regulatory staff.
Re-evaluation of products previously approved as ‘intended copy’ biological drugs according to regulations specific to biosimilars.

The panel members hope these recommendations will be implemented widely in order to facilitate the appropriate review, approval and safe use of biosimilars across Latin America.

Editor’s comment
It should be noted that ‘follow-on biologics’ approved in Latin America might not have been authorized following as strict a regulatory process as is required for approval of biosimilars in the EU. EMA regulatory requirements ensure the same high standards of quality, safety and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product.

If you are interested in contributing a research paper in a similar area to GaBI Journal, please send us your submission here.

Regulation of similar biotherapeutic products in Latin America

Medicines spending in Brazil

Reference
1. Azevedo VF, Mysler E, Álvarez AA, Hughes J, Flores-Murrieta FJ, Ruiz de Castilla EM. Recommendations for the regulation of biosimilars and their implementation in Latin America. Generics and Biosimilars Initiative Journal (GaBI Journal). 2014;3(3):143-8. doi:10.5639/gabij.2014.0303.032

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Comments (2)

Post your comment

Posted 24/09/2014 by Justyna K, GaBI Online Editorial Office

Response to 'Biosimilar in Latin America'

Dear Mr Krimer, Thank you for your valuable comments. We would be delighted if you would consider submitting a <i>Letter to the Editor</i> to <i>GaBI Journal</i> to share your insight and knowledge on the subject. If interested, please feel free to reach us at editorial@gabi-journal.net. Thank you again and we hope to hear from you soon. Best regards, Justyna

Posted 31/08/2014 by Alejandro Krimer

Biosimilar in Latin America

The author of the comment has a very poor idea about past and present of Biosimilars in Latam. Million of doses sold in Latam, Asia an African countries WITHOUT ANY ADVERSE EFFFECTS REPORTED, must not be ignored. The fact of no patent laws in most of countries allow the development of a growing industry, comprising not only produce the biosimilars but developing an important number of Human Resources devoted to this field, either in industry and Regulatory Authorities. If in the developed countries a lot of scientific work is accepted from retrospective analysis, the same criteria should be used for Biosimilars. I have worked several years in Argentinian companies developing biosimilars and we get biosimilars effective and safe (and cheaper than originals). The last question the originator's companies try to avoid in the discussion is the lot-to-lot variation in the quality of the original molecules produced either in Europe or USA. This variation is in general as broader as most of biosimilars existing in the Market. Sincerely yours, Alejandro Krimer